Monte Rosa Therapeutics Initiates Dosing in MRT-6160 Study
MRT-6160 is a uniquely designed VAV1-directed molecular glue degrader, offering a new therapeutic approach for tackling systemic and neurological autoimmune and inflammatory disorders.
Initial findings from the Phase 1 clinical trial, including biomarker data that illustrate pharmacodynamic effects, are expected to be released in early 2025.
BOSTON, Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company in the clinical stage focused on pioneering molecular glue degrader (MGD)-based therapies, has announced that it has begun dosing the first participants in its Phase 1 clinical trial. This trial employs single and multiple ascending dose (SAD/MAD) methodologies with healthy volunteers and is designed to assess MRT-6160, a VAV1-directed MGD specifically aimed at treating systemic and neurological autoimmune disorders. Preliminary results from this Phase 1 study are anticipated in early 2025.
“We are thrilled to start our Phase 1 clinical evaluation of MRT-6160, a powerful and highly selective VAV1-directed MGD that can be taken orally,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. “We believe MRT-6160 is the first rationally designed MGD being investigated for clinical applications beyond oncology. Our MGD approach effectively targets proteins that have traditionally been challenging to address with standard treatments. By focusing on VAV1, a critical regulator associated with T- and B-cell receptor functions, MRT-6160 offers a new opportunity to manage a range of autoimmune and inflammatory conditions. This Phase 1 trial is designed to provide vital insights into safety, pharmacokinetics, the degradation of VAV1 protein, and important downstream pharmacodynamic markers such as CD69, IL-2, IL-6, and IL-17, which will further inform our clinical strategy. We look forward to sharing initial clinical findings from this study in early 2025, followed by potential proof-of-concept trials for conditions like ulcerative colitis and rheumatoid arthritis, among others.”
The development of MRT-6160 is supported by promising preclinical evidence across various models that simulate autoimmune or inflammatory conditions. Additionally, preclinical GLP toxicology data suggest that MRT-6160 could offer a distinctive therapeutic profile for addressing T-cell, T/B-cell, and Th17-mediated systemic and neurological autoimmune diseases. The compound has shown an ability to effectively degrade VAV1 in vitro within human T and B cells and has produced positive results in several preclinical models related to autoimmune disorders, including those mimicking inflammatory bowel conditions, rheumatoid arthritis, and multiple sclerosis.
About MRT-6160
MRT-6160 is an investigational molecular glue degrader that targets VAV1, recognized for its potency, high selectivity, and oral bioavailability. Preclinical studies have demonstrated significant degradation of VAV1 without any observed adverse effects on other proteins. VAV1, part of the Rho-family of guanine nucleotide exchange factors, plays a crucial role in the signaling pathways downstream of T- and B-cell receptors. Its expression is limited to blood and immune cells, including T and B cells. Findings from preclinical research indicate that strategically targeting VAV1 through MGD leads to modulation of T- and B-cell receptor-related activities, observable both in vitro and in vivo. This modulation is characterized by a significant decrease in cytokine secretion, which are essential proteins involved in maintaining autoimmune responses. Moreover, VAV1-targeted MGDs have shown promising results in preclinical models addressing autoimmune conditions, suggesting their potential therapeutic applications across a wide range of systemic and neurological autoimmune disorders, such as inflammatory bowel disease, rheumatoid arthritis, and various dermatological conditions.
About Monte Rosa
Monte Rosa Therapeutics is dedicated to advancing innovative molecular glue degrader (MGD) treatments aimed at helping patients facing severe diseases in oncology, autoimmune, and inflammatory areas. MGDs are small-molecule protein degraders that have the potential to tackle a variety of illnesses that other treatment modalities have struggled to effectively manage. The company’s proprietary QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery platform utilizes AI-driven chemistry, diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and systematically design MGDs with unparalleled selectivity. Through the QuEEN discovery model, Monte Rosa gains access to a wide array of validated biology across multiple therapeutic areas. Additionally, Monte Rosa has the industry's leading MGD development pipeline, which encompasses oncology, autoimmune disorders, and more, along with a strategic partnership with Roche to identify and develop MGDs for previously undruggable cancer and neurological disease targets. For more information, you can visit www.monterosatx.com.
Contact Information
Investors:
Andrew Funderburk
ir@monterosatx.com
Media:
Cory Tromblee, Scient PR
media@monterosatx.com
Frequently Asked Questions
1. What is MRT-6160 designed to target?
MRT-6160 is engineered to target VAV1, a key regulator involved in T- and B-cell receptor activity, which is relevant for various autoimmune disorders.
2. When are initial results from the MRT-6160 Phase 1 study expected?
The initial Phase 1 clinical results, along with biomarker data, are anticipated to be disclosed in early 2025.
3. What conditions could benefit from MRT-6160?
MRT-6160 may be beneficial for autoimmune diseases such as ulcerative colitis, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.
4. How is MRT-6160 different from traditional treatments?
MRT-6160 utilizes a molecular glue degrader approach, potentially overcoming limitations faced by conventional treatments in targeting difficult-to-drug proteins.
5. Where can I find more information about Monte Rosa Therapeutics?
More information about Monte Rosa Therapeutics and its innovative therapies can be found at its official website: www.monterosatx.com.
